PCVX MEXC RealStocks
Own real PCVX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1

Last updated: 2026-11-19 02:28:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vaxcyte, Inc. (PCVX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $58.57, with a market capitalization of $9.75B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $42.40 to $90.75. This page covers its latest market performance, valuation, price trends and company information.
$9.75B | |
$59.16 | |
$61.54 | |
$57.65 | |
$59.40 | |
868.81K | |
2.19M | |
-- | |
$90.75 | |
$42.40 | |
-- | |
2026-09-30 |
Vaxcyte, Inc. (PCVX) last closed at $58.57 as of 2026-11-19 01:00:00, down 1.45% ($0.86) from the previous close of $59.40.
During the latest regular trading session, PCVX traded between $57.65 and $61.54, with a volume of 868.81K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Vaxcyte, Inc. (PCVX) moved from $67.53 to $58.57, representing a decline of 13.27% ($8.96).
The stock traded between $57.65 and $68.92 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.09 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 33.4%
PCVX is currently trading at $58.57, placing it 33.4% of the way from its 52-week low of $42.40 to its 52-week high of $90.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 507 |
| CEO | Grant E. Pickering |
| Founded | 2013 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vaxcyte, Inc. (PCVX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PCVX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PCVX shares and USD.
PCVX Shares to USD
1.00 PCVX shares = 58.57 USD
Calculations are estimates based on the latest available price and are for reference only.